S&P 500   4,022.91 (-0.02%)
DOW   32,344.38 (+0.46%)
QQQ   300.80 (-0.38%)
AAPL   146.67 (-0.30%)
MSFT   263.91 (+1.07%)
FB   202.65 (+2.03%)
GOOGL   2,301.75 (-0.83%)
AMZN   2,236.60 (-1.08%)
TSLA   732.57 (-4.81%)
NVDA   175.38 (-0.95%)
BABA   87.67 (-0.36%)
NIO   14.84 (+3.70%)
AMD   95.88 (+0.80%)
CGC   5.79 (-2.20%)
MU   71.43 (-0.68%)
T   20.33 (+2.47%)
GE   75.14 (+0.12%)
F   13.18 (-2.37%)
DIS   106.16 (-1.09%)
AMC   11.81 (+0.17%)
PFE   51.02 (+2.20%)
PYPL   78.51 (-0.41%)
NFLX   188.32 (+0.36%)
S&P 500   4,022.91 (-0.02%)
DOW   32,344.38 (+0.46%)
QQQ   300.80 (-0.38%)
AAPL   146.67 (-0.30%)
MSFT   263.91 (+1.07%)
FB   202.65 (+2.03%)
GOOGL   2,301.75 (-0.83%)
AMZN   2,236.60 (-1.08%)
TSLA   732.57 (-4.81%)
NVDA   175.38 (-0.95%)
BABA   87.67 (-0.36%)
NIO   14.84 (+3.70%)
AMD   95.88 (+0.80%)
CGC   5.79 (-2.20%)
MU   71.43 (-0.68%)
T   20.33 (+2.47%)
GE   75.14 (+0.12%)
F   13.18 (-2.37%)
DIS   106.16 (-1.09%)
AMC   11.81 (+0.17%)
PFE   51.02 (+2.20%)
PYPL   78.51 (-0.41%)
NFLX   188.32 (+0.36%)
S&P 500   4,022.91 (-0.02%)
DOW   32,344.38 (+0.46%)
QQQ   300.80 (-0.38%)
AAPL   146.67 (-0.30%)
MSFT   263.91 (+1.07%)
FB   202.65 (+2.03%)
GOOGL   2,301.75 (-0.83%)
AMZN   2,236.60 (-1.08%)
TSLA   732.57 (-4.81%)
NVDA   175.38 (-0.95%)
BABA   87.67 (-0.36%)
NIO   14.84 (+3.70%)
AMD   95.88 (+0.80%)
CGC   5.79 (-2.20%)
MU   71.43 (-0.68%)
T   20.33 (+2.47%)
GE   75.14 (+0.12%)
F   13.18 (-2.37%)
DIS   106.16 (-1.09%)
AMC   11.81 (+0.17%)
PFE   51.02 (+2.20%)
PYPL   78.51 (-0.41%)
NFLX   188.32 (+0.36%)
S&P 500   4,022.91 (-0.02%)
DOW   32,344.38 (+0.46%)
QQQ   300.80 (-0.38%)
AAPL   146.67 (-0.30%)
MSFT   263.91 (+1.07%)
FB   202.65 (+2.03%)
GOOGL   2,301.75 (-0.83%)
AMZN   2,236.60 (-1.08%)
TSLA   732.57 (-4.81%)
NVDA   175.38 (-0.95%)
BABA   87.67 (-0.36%)
NIO   14.84 (+3.70%)
AMD   95.88 (+0.80%)
CGC   5.79 (-2.20%)
MU   71.43 (-0.68%)
T   20.33 (+2.47%)
GE   75.14 (+0.12%)
F   13.18 (-2.37%)
DIS   106.16 (-1.09%)
AMC   11.81 (+0.17%)
PFE   51.02 (+2.20%)
PYPL   78.51 (-0.41%)
NFLX   188.32 (+0.36%)
NASDAQ:SPPI

Spectrum Pharmaceuticals (SPPI) Stock Forecast, Price & News

$0.77
+0.00 (+0.31%)
(As of 05/16/2022 03:02 PM ET)
Add
Compare
Today's Range
$0.76
$0.80
50-Day Range
$0.71
$1.40
52-Week Range
$0.60
$4.54
Volume
41,337 shs
Average Volume
3.91 million shs
Market Capitalization
$136.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.23
30 days | 90 days | 365 days | Advanced Chart
Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Spectrum Pharmaceuticals logo

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Henderson, Nevada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SPPI
CUSIP
84763A10
Employees
163
Year Founded
2002

Sales & Book Value

Annual Sales
N/A
Book Value
$0.29 per share

Profitability

Net Income
$-158.63 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
171,551,000
Market Cap
$136.83 million
Optionable
Optionable

Company Calendar

Last Earnings
3/17/2022
Today
5/16/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

493rd out of 1,423 stocks

Pharmaceutical Preparations Industry

221st out of 678 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

Is Spectrum Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Spectrum Pharmaceuticals stock.
View analyst ratings for Spectrum Pharmaceuticals
or view top-rated stocks.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Spectrum Pharmaceuticals
.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its quarterly earnings results on Thursday, March, 17th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.05. During the same period last year, the business posted ($0.36) earnings per share.
View Spectrum Pharmaceuticals' earnings history
.

What price target have analysts set for SPPI?

3 Wall Street analysts have issued 12-month price objectives for Spectrum Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 417.3% from the stock's current price.
View analysts' price targets for Spectrum Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the following people:
  • Mr. Thomas J. Riga, Pres, CEO & Director (Age 46, Pay $1.03M) (LinkedIn Profile)
  • Mr. Keith M. McGahan J.D., L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 46, Pay $842.19k) (LinkedIn Profile)
  • Dr. Francois J. Lebel FRCPC, M.D., Exec. VP & Chief Medical Officer (Age 70, Pay $926.76k)
  • Mr. Bimal R. Shah, VP of Corp. & Bus. Devel.
  • Dr. Lyndah K. Dreiling M.B.A., M.D., Sr. VP of Clinical Devel.
What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals CEO Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among Spectrum Pharmaceuticals' employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.91%), Vanguard Group Inc. (4.50%), State Street Corp (1.88%), Northern Trust Corp (0.83%), Renaissance Technologies LLC (0.79%) and Panagora Asset Management Inc. (0.48%). Company insiders that own Spectrum Pharmaceuticals stock include Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Seth H Z Fischer, Thomas J Riga and William Ashton.
View institutional ownership trends for Spectrum Pharmaceuticals
.

Which major investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., State Street Corp, Principal Financial Group Inc., Invesco Ltd., Bank of New York Mellon Corp, Dimensional Fund Advisors LP, and Rhumbline Advisers. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Francois Lebel, Keith M Mcgahan, Kurt A Gustafson, Seth H Z Fischer, and Thomas J Riga.
View insider buying and selling activity for Spectrum Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, CM Management LLC, Sargent Investment Group LLC, Acadian Asset Management LLC, Ergoteles LLC, KBC Group NV, Panagora Asset Management Inc., and McDonald Partners LLC.
View insider buying and selling activity for Spectrum Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $0.77.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals has a market capitalization of $136.99 million. The biotechnology company earns $-158.63 million in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does Spectrum Pharmaceuticals have?

Spectrum Pharmaceuticals employs 163 workers across the globe.

When was Spectrum Pharmaceuticals founded?

Spectrum Pharmaceuticals was founded in 2002.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is www.sppirx.com.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at (702) 835-6300, via email at [email protected], or via fax at 702-260-7405.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.